Clinical trials: Asthma; Eosinophilic
Bone and Joint Infection, Treated by Daptomycin
Daptomycin > 6 mg/kg/Day as Salvage Therapy in Patients With Complex Bone and Joint Infection: Cohort Study in a Regionalreference Center
The choice of antimicrobial therapy to treat complex bone and joint infections (BJI) is challenging, requiring consideration of: (i) the problem of bone diffusion; (ii) the necessity of using antimicrobials active against…
- Trial name
- NCT03209934
- Volunteers
- 43 people
- Sponsor
- Hospices Civils de Lyon
Severe Eosinophilic Asthma, Psychological Distress
Severe Asthma, MepolizumaB and Affect: SAMBA Study
This is a real-life pragmatic non-randomised study to explore the impact of mepolizumab on the emotional and affective outcomes of patients with severe eosinophilic asthma and their partners.
- Conditions
- Severe Eosinophilic Asthma, Psychological Distress, Anxiety, Depression
- Trial name
- SAMBA (NCT04680611)
- Testing
- no study intervention. Patients receive standard clinical care
- Where
- 6 sites in United Kingdom
- Volunteers
- 120 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Eosinophilic Asthma
A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma
The primary objective of this study is to determine whether reslizumab is more effective than placebo in reducing the number of clinical asthma exacerbations (CAEs) in patients with eosinophilic asthma.
- Trial name
- NCT01285323
- Testing
- Reslizumab
- Where
- 104 sites in United States, Argentina and 13 more
- Volunteers
- 464 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Eosinophilic Asthma
A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma
This Phase 2b study is designed to evaluate the safety and efficacy of KT-621 in participants with uncontrolled moderate to severe eosinophilic asthma.
- Trial name
- BREADTH (NCT07323654)
- Testing
- KT-621
- Where
- 81 sites in United States, Argentina and 11 more
- Volunteers
- 264 people
- Sponsor
- Kymera Therapeutics, Inc.
Asthma
A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic Inflammation
The purpose of this study is to investigate the onset and maintenance of effect of benralizumab on lung function, blood eosinophils, asthma control metrics and quality of life during 12-week treatment in patients with…
- Trial name
- SOLANA (NCT02869438)
- Testing
- Benralizumab
- Where
- 54 sites in United States, Chile and 4 more
- Volunteers
- 233 people
- Sponsor
- AstraZeneca
Asthma
A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype
This study will assess the efficacy and safety of GSK3511294 (Depemokimab) as an adjunctive therapy in participants with severe uncontrolled asthma with an eosinophilic phenotype.
- Trial name
- SWIFT-2 (NCT04718103)
- Testing
- GSK3511294
- Where
- 129 sites in United States, Australia and 9 more
- Volunteers
- 397 people
- Sponsor
- GlaxoSmithKline
Asthma
Inflammation Following Mepolizumab and Oral Corticosteroids in Asthma
The aim of the project is to study the persistence of inflammation after addition of an interleukin-5 (IL-5) blocker in severe eosinophilic asthma as a study of untreated pathways in these patients.
- Trial name
- MAPLE (NCT03610685)
- Testing
- Prednisolone
- Where
- United Kingdom
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- NHS Greater Glasgow and Clyde
Eosinophilic Asthma
A Pragmatic Study to Investigate the Efficacy and Safety of Mepolizumab in Severe Uncontrolled Asthma in Brazil
The anti-interleukin-5 monoclonal antibody mepolizumab is approved as an add-on therapy in Europe, Canada, USA, and other countries, to standard of care for the treatment of patients with severe eosinophilic asthma.
- Trial name
- NCT04228588
- Testing
- Mepolizumab 100 MG [Nucala]
- Where
- Brazil
- Volunteers
- 18 people
- Sponsor
- University of Sao Paulo General Hospital
Asthma
Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study
Reslizumab is a type of medicine called a monoclonal antibody that is made in the research clinic; it works by blocking a specific protein in the body called interleukin-5.
- Trial name
- RITE (NCT02947945)
- Testing
- Reslizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Jewish Health
Severe Asthma
Prevalence of the Eosinophilic Phenotype Among Severe Asthma Patients
The purpose of this cross-sectional, multicenter study is to determine the prevalence of an eosinophilic phenotype of blood eosinophil count ≥ 300 cells/mm3 among severe asthma patients who attend to sites specialized in the…
- Trial name
- PREPARE (NCT03931954)
- Where
- 18 sites in Argentina, Chile and 4 more
- Volunteers
- 794 people
- Sponsor
- AstraZeneca
Asthma
Study of Mepolizumab Autoinjector in Asthmatics
This study is aimed to assess the correct real-world use of an autoinjector for the repeat self-administration of mepolizumab SC, so to improve subject / physician convenience and to enable repeat dose self injection themselves…
- Trial name
- NCT03099096
- Testing
- Mepolizumab
- Where
- 38 sites in United States, Australia and 5 more
- Volunteers
- 159 people
- Sponsor
- GlaxoSmithKline
Asthma
Follow-up of Mild Eosinophilic Asthma
Asthma is a chronic respiratory disease affecting approximately 10% of the population, the majority of patients with very mild to mild asthma.
- Trial name
- NCT04650503
- Testing
- No intervention
- Where
- Canada
- Volunteers
- 80 people
- Sponsor
- Laval University
Severe Eosinophilic Asthma
Effect of OC000459 on Eosinophilic Airway Inflammation in Severe Asthma
The aim is to study the effect of OC000459 on eosinophilic airway inflammation and asthma control in subjects with severe, refractory eosinophilic asthma.
- Trial name
- NCT02560610
- Testing
- OC000459
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma; Eosinophilic, Severe Asthma
Efficacy of Mepolizumab in Severe Asthmatics on a Long Term (MESILICO)
Interleukin (IL)-5 is the main cytokine responsible for the activation of eosinophils, hence therapeutic strategies have been investigated and developed for clinical use.
- Conditions
- Asthma; Eosinophilic, Severe Asthma, Late-Onset Asthma
- Trial name
- MESILICO (NCT04612556)
- Testing
- Mepolizumab 100 MG [Nucala]
- Where
- Greece
- Volunteers
- 45 people
- Sponsor
- Aristotle University Of Thessaloniki
Asthma Persistent, Asthma, Allergic
Identifying Serum Cytokine Profiles of Distinct Inflammatory Phenotypes in Severe Asthma
The aim of this study is to determine and compare serum cytokine levels of six different severe asthma inflammatory phenotypes differentiated by their atopy, peripheral eosinophilia and/or chronic rhinosinusitis and/or nasal…
- Conditions
- Asthma Persistent, Asthma, Allergic, Eosinophilic Asthma, Chronic Rhinosinusitis (Diagnosis)
- Trial name
- NCT03563521
- Where
- Turkey (Türkiye)
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- TC Erciyes University
Eosinophilic Asthma, Asthma; Eosinophilic
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.
This study will assess the efficacy and safety of dexpramipexole as an adjunctive oral therapy in participants with inadequately controlled asthma with an eosinophilic phenotype and a history of asthma exacerbations.
- Conditions
- Eosinophilic Asthma, Asthma; Eosinophilic, Asthma
- Trial name
- EXHALE-2 (NCT05763121)
- Testing
- Dexpramipexole Dihydrochloride
- Where
- 401 sites in United States, Argentina and 18 more
- Volunteers
- 1,061 people
- Sponsor
- Areteia Therapeutics
Asthma; Eosinophilic, Airway Remodeling
BenRalizumab Effect on Airway Remodeling in Severe asTHma
Response to biologic therapies in severe asthma is variable, with patients being either non-responders, responders or super-responders. There is currently no explanation for this broad variation in response.
- Trial name
- BREATH (NCT06288516)
- Testing
- Benralizumab 30 mg/ml
- Where
- Greece
- Volunteers
- 36 people
- Sponsor
- Aristotle University Of Thessaloniki
Severe Asthma
BRazilian Asthmatics Patients EOSinophilic Profile (BRAEOS)
Asthma is a complex and heterogeneous disease. Severe asthma is recognised as a major unmet need that poses a great burden on the healthcare system.
- Trial name
- BRAEOS (NCT03925415)
- Where
- 6 sites in Brazil
- Volunteers
- 414 people
- Sponsor
- AstraZeneca
Airway Auto Immunity in Asthma
IL-13 Blockade and Airway Autoimmunity in Asthma
It has been observed that certain section of patients having severe to moderate Asthma, do not benefit from oral corticosteroids and IL-5 blocking biologics.
- Trial name
- IL-SAA (NCT05564078)
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- McMaster University
Asthma
A Safety and Efficacy Study of Mepolizumab in Subjects With Severe Asthma
Mepolizumab, a humanized monoclonal antibody, has been developed as an add-on treatment for subjects with severe asthma with eosinophilic inflammation.
- Trial name
- NCT03562195
- Testing
- Mepolizumab 100 milligrams, Salbutamol
- Where
- 42 sites in China
- Volunteers
- 300 people
- Sponsor
- GlaxoSmithKline